all the information, none of the junk | biotech • healthcare • life sciences

Who Should Biotech Pros Follow on Twitter? An Update for 2013

(Page 3 of 3)

insist on anonymity, but love to play the role of ventriloquist, being the ones to make other people’s lips move. Not Martin Shkreli, at least on Twitter. Shkreli, who’s also the CEO of a biotech company called Retrophin, puts his name out there and lets his opinions fly, for better or worse. “$JNJ finally at $90+. Buffett should have been more patient despite crap management team,” Shkreli recently wrote.

Other commentators:

@ScottGottliebMD Scott Gottlieb is a physician, author, a fellow at the American Enterprise Institute, and the former deputy commissioner of the FDA under George W. Bush. He’s a conservative, and he hammers away at the Affordable Care Act every chance he gets. Agree or disagree, Gottlieb’s point of view is well worth reading.

@biologypartners David Maizenberg follows intellectual property issues as a consultant, marketer, and writer.

@cbtadvisors Steve Dickman is a Boston-based biotech consultant. He recently tweeted out a link to a guest post he wrote for Xconomy about how venture capitalists are turning to royalty financing as a new strategy to lift their returns.

@bengoldacre Ben Goldacre is an influential critic of the pharma industry, with more followers (289,000) than probably every pharma company on Twitter combined. Goldacre, based in London, recently mocked Pfizer in the following message. “Dear NHS please give all your money lol love pfizer RT @David_E14: Pfizer’s ad at Westminster tube pic.twitter.com/97z8u0V0zf I’m sure he irritates plenty of folks in pharma, but his voice is one that can’t be ignored.

@LifeSciIP Konstantin Linnik is an IP attorney in Boston at Nutter, McClennen and Fish. He recently blogged about the ramifications of the high-profile Myriad case on gene patenting that went before the Supreme Court.

@AlecGaffney Alexander Gaffney writes about the regulatory bodies that affect biotech in Washington D.C. He also recently compiled a list of 300 accounts worth following for folks who look through a regulatory lens.

@oli_rayner Oli Rayner is a patient with cystic fibrosis in the U.K., with a background in investment banking. He’s a smart consumer and commentator.

@Paul_Sonnier Paul Sonnier is a tireless promoter for all things that fall under the banner of digital health. He sees a future full of wireless health apps and sensors keeping us all healthy. I think he goes to bed dreaming about sleep sensors, and wakes up dreaming about gizmos to monitor your caffeine intake.

Single PageCurrently on Page: 1 2 3 previous page

By posting a comment, you agree to our terms and conditions.

3 responses to “Who Should Biotech Pros Follow on Twitter? An Update for 2013”

  1. Theral says:

    I could recommend a host of others. But I’ll keep it to one since you haven’t listed a category for this: @davidbrin. Beyond the business, policy, science, media, etc., are the sci-fi writers. They do the heavy lifting.

  2. Thanks, Theral. I need to carve out a little more time for sci-fi reading.

  3. Amarshall says:

    You might also follow certain stuffy outdated journals @naturebiotech